MCID: MNN020
MIFTS: 45

Meningococcal Infection

Categories: Infectious diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Meningococcal Infection

MalaCards integrated aliases for Meningococcal Infection:

Name: Meningococcal Infection 52 17 32
Meningococcal Infections 42 71

Classifications:



External Ids:

ICD10 32 A39 A39.9
UMLS 71 C0025303

Summaries for Meningococcal Infection

MedlinePlus : 42 Meningococci are a type of bacteria that cause serious infections. The most common infection is meningitis, which is an inflammation of the thin tissue that surrounds the brain and spinal cord. Meningococci can also cause other problems, including a serious bloodstream infection called sepsis. Meningococcal infections can spread from person to person. Risk factors include Age - it is more common in infants, teens, and young adults Living in close quarters, such as in college dorms or military settings Certain medical conditions, such as not having a spleen Travel to areas where meningococcal disease is common In its early stages, you may have flu-like symptoms and a stiff neck. But the disease can progress quickly and can be fatal. Early diagnosis and treatment are extremely important. Lab tests on your blood and cerebrospinal fluid can tell if you have it. Treatment is with antibiotics. Since the infection spreads from person to person, family members may also need to be treated. A vaccine can prevent meningococcal infections.

MalaCards based summary : Meningococcal Infection, also known as meningococcal infections, is related to waterhouse-friderichsen syndrome and neisseria meningitidis infection, and has symptoms including fever and pruritus. An important gene associated with Meningococcal Infection is C7 (Complement C7), and among its related pathways/superpathways are Aldosterone synthesis and secretion and G-protein signaling G-Protein alpha-i signaling cascades. The drugs Lactitol and Complement Factor H have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and spleen, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 74 Neisseria meningitidis, often referred to as meningococcus, is a Gram-negative bacterium that can cause... more...

Related Diseases for Meningococcal Infection

Diseases related to Meningococcal Infection via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 148)
# Related Disease Score Top Affiliating Genes
1 waterhouse-friderichsen syndrome 11.8
2 neisseria meningitidis infection 11.8
3 meningitis 11.6
4 properdin deficiency, x-linked 11.6
5 complement factor h deficiency 11.2
6 meningococcal meningitis 11.1
7 meningococcemia 10.5
8 toxic shock syndrome 10.4
9 bacterial meningitis 10.4
10 trimethoprim allergy 10.4 GSR G6PD
11 exanthem 10.4
12 lymphosarcoma 10.3 GSR G6PD
13 disseminated intravascular coagulation 10.3
14 pericarditis 10.3
15 purpura 10.3
16 bacterial infectious disease 10.3
17 brain edema 10.3
18 arthritis 10.3
19 resting heart rate, variation in 10.3 ADRB2 ADRB1
20 diabetic cataract 10.3 GSR G6PD
21 ocular hypotension 10.2 ADRB2 ADRB1
22 complement deficiency 10.2
23 haemophilus influenzae 10.2
24 prostatic adenoma 10.2 ADRB2 ADRB1
25 male reproductive organ benign neoplasm 10.2 ADRB2 ADRB1
26 nasopharyngitis 10.2
27 meningoencephalitis 10.2
28 hydrops, lactic acidosis, and sideroblastic anemia 10.2
29 purpura fulminans 10.2
30 septic arthritis 10.2
31 myocarditis 10.2
32 vasculitis 10.2
33 posterior urethral valves 10.1 AGTR1 AGT
34 complement component 7 deficiency 10.1
35 acute mountain sickness 10.1 AGTR1 ADRB2
36 plantar fascial fibromatosis 10.1 AGTR1 AGT
37 fibromuscular dysplasia 10.1 AGTR1 AGT
38 renal artery disease 10.1 AGTR1 AGT
39 familial hypertension 10.1 AGTR1 AGT
40 anuria 10.1 AGTR1 AGT
41 ocular motor apraxia 10.1
42 complement component 5 deficiency 10.1
43 complement component deficiency 10.1
44 properdin deficiency 10.1
45 renal tubular dysgenesis 10.0 AGTR1 AGT
46 malignant hypertension 10.0 AGTR1 AGT
47 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.0
48 branchiootic syndrome 1 10.0
49 malaria 10.0
50 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.0

Graphical network of the top 20 diseases related to Meningococcal Infection:



Diseases related to Meningococcal Infection

Symptoms & Phenotypes for Meningococcal Infection

UMLS symptoms related to Meningococcal Infection:


fever, pruritus

MGI Mouse Phenotypes related to Meningococcal Infection:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.61 ADRB1 ADRB2 AGT AGTR1 G6PD GSR
2 homeostasis/metabolism MP:0005376 9.28 ADD1 ADRB1 ADRB2 AGT AGTR1 CPB2

Drugs & Therapeutics for Meningococcal Infection

Drugs for Meningococcal Infection (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 40)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lactitol Investigational Phase 4 585-86-4, 585-88-6 493591
2 Complement Factor H Phase 4
3 Vaccines Phase 4
4 Immunologic Factors Phase 4
5 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
6 Cathartics Phase 4
7 Gastrointestinal Agents Phase 4
8 Laxatives Phase 4
9
Histidine Investigational, Nutraceutical Phase 4 71-00-1 6274
10
Hydroxocobalamin Approved Phase 3 13422-51-0 11953898 15589840
11
Tetracycline Approved, Vet_approved Phase 3 60-54-8 5353990
12
Cyanocobalamin Approved, Nutraceutical Phase 3 68-19-9 44176380
13
Cobalamin Experimental Phase 3 13408-78-1 6857388
14 Vitamin B 12 Phase 3
15 Vitamin B12 Phase 3
16 Anti-Infective Agents Phase 3
17 Anti-Bacterial Agents Phase 3
18 Pharmaceutical Solutions Phase 3
19
Iron Approved, Experimental Phase 2 7439-89-6, 15438-31-0 23925 27284
20
Edetic Acid Approved, Vet_approved Phase 2 60-00-4, 62-33-9 6049
21
Pentetic acid Approved Phase 2 67-43-6
22 Antipyretics Phase 2
23 PENTA Phase 2
24 Chelating Agents Phase 2
25 Iron Chelating Agents Phase 2
26 Protective Agents Phase 2
27 Antidotes Phase 2
28 Hops Approved Phase 1
29
Aluminum hydroxide Approved, Investigational Phase 1 21645-51-2
30 Adjuvants, Immunologic Phase 1
31 Anti-Ulcer Agents Phase 1
32 Antacids Phase 1
33
Ceftriaxone Approved 73384-59-5 5479530 5361919
34 Natriuretic Agents
35 Natriuretic Peptide, Brain
36 Antitubercular Agents
37 Antibiotics, Antitubercular
38 Antibodies
39 Immunoglobulins
40 Complement System Proteins

Interventional clinical trials:

(show top 50) (show all 209)
# Name Status NCT ID Phase Drugs
1 A Phase IV, Single Center, Open-Label, Controlled, Randomized Study to Evaluate the Memory Response of Children Previously Vaccinated With Chiron Meningococcal C Conjugate Vaccine, Menjugate® and Describe the Kinetic of the Antibody Response and Maturation on Days 2-7 and 28 After Challenge With Pasteur Merieux Meningococcal A/C Polysaccharide Vaccine or Menjugate® Unknown status NCT00262015 Phase 4
2 Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba) in Adults at Increased Risk of Meningococcal Disease Because of Occupational Exposure Unknown status NCT02569632 Phase 4
3 A Phase IV, Multi-Center, Controlled Open-Label Study to Evaluate the Safety, Tolerability and Immunogenicity of a Commercially Available Meningococcal C Vaccine When Given as First, Third or Fourth Immunization to Children 32-40 Months of Age Completed NCT00310635 Phase 4
4 A Phase IV, Single Centre, Open-label Study to Investigate the Kinetics of the B Cell Response to the First and the Third Immunization With Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Infants at 2, 3 and 4 Months of Age Completed NCT00310700 Phase 4
5 A Phase IV,Multi-Center,Open-Label,Unrandomized Study to Evaluate the Persistence of Antibody Response to N.Meningitidis Group C,Before & After 2 Doses of the Conjugate Pneumococcal Vaccine,in Children Seven Months & Older Who Previously Received Immunization With Chiron Meningococcal C Conjugate Vaccine & a Hexavalent Infant Vaccine According to the Applicable Infant Immunization Schedule Completed NCT00316654 Phase 4
6 A Phase IV, Single Centre, Open-label Study to Evaluate the Persistence of Antibodies in Adolescents 14-16 Years of Age, Vaccinated With Chiron Meningococcal C Conjugate Vaccine During the 1999-2001 UK MenCC Immunization Campaign, at One Year After Either a Challenge Dose of Aventis Pasteur MSD Meningococcal A/C Polysaccharide Vaccine or a Booster Dose of MenC Vaccine, in Parallel to Subjects Aged 11-20 Evaluated at 4 Years After Vaccination During the 1999-2001 UK MenCC Immunization Campaign Completed NCT00310687 Phase 4
7 Randomized, Open Label, Active Control, Parallel Assignment Clinical Trial to Evaluate the Immunogenicity of Polysaccharide Meningococcal C Vaccines Conjugated With Tetanus Toxoid or CRM197 Given as a Booster Dose at 14-18 Months of Life. Completed NCT00392808 Phase 4
8 A Phase IV, Single Centre, Open-label Study to Investigate the Kinetics of the B Cell Response to the C Saccharide Component of Chiron's Meningococcal C Conjugate Vaccine Administered to Healthy Children at Least 12 Months of Age After Priming With a Commercially Available Men ACWY Conjugate Vaccine at 2, 3 and 4 Months of Age Completed NCT00310713 Phase 4
9 An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age. Completed NCT01659996 Phase 4
10 Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately Four Years Earlier Completed NCT02633787 Phase 4
11 Safety and Immunogenicity of Intradermal, and Low-dose Subcutaneous vs Subcutaneous Administration of Menomune® - A/C/Y/W-135 Completed NCT00850603 Phase 4
12 Response of United Kingdom (UK) Infants to a Reduced Primary Schedule With Meningococcal C and Pneumococcal Conjugate Vaccines Completed NCT00197808 Phase 4
13 Immunogenicity and Safety of Two-Dose Series of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284; Menactra®) in Japanese Healthy Adult Subjects Completed NCT02591290 Phase 4
14 A Phase IV, Partially Double-blind Study to Demonstrate Non-inferiority of GSK Biologicals' Mencevax™ ACWY (New Process) Versus Mencevax™ ACWY (Current Process) When Administered as a Single Dose to Subjects Aged 2-30 Yrs Completed NCT00227422 Phase 4
15 A Phase IV, Open-Label, Multi-Center Study to Evaluate the Safety and the 1-year Persistence of Antibody Response Among Children Who Received 4 Doses of the GSK MenACWY Conjugate Vaccine at 2, 4, 6 and 12 Months of Age in South Korea Completed NCT02446691 Phase 4
16 Meningococcal (Groups A, C, Y, W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) Post-Marketing Safety Study in Healthy Children (2-11 Years), Adolescents (12-17 Years) and Adults (18-55 Years) in the Philippines Completed NCT01270503 Phase 4
17 A Phase IV, Open-label, Controlled, Multi-center Study to Evaluate the 5-year Antibody Persistence Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine at 2 to 10 Years of Age and to Assess the Immune Response to a Single Dose of Novartis MenACWY Conjugate Vaccine Completed NCT01823536 Phase 4
18 A Multicenter Post Marketing Surveillance Study to Monitor the Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ACWY Conjugate Vaccine(MenACWY-CRM) Administered According to the Prescribing Information to Healthy Subjects From 2 Months to 55 Years of Age in the Republic of South Korea. Completed NCT01766206 Phase 4
19 Safety and Immunogenicity of Sanofi Pasteur Meningococcal (Groups A and C) Polysaccharide Vaccine Versus Lanzhou Institute for Biological Products Meningococcal (Groups A and C) Polysaccharide Vaccine in Children 2-6 Years of Age in China Completed NCT01430611 Phase 4
20 Multicentric, Surveillance Study to Monitor Safety of GSK Biologicals' Purified Meningococcal Polysaccharide Vaccine of Serogroups ACWY in 3,000 Filipino Subjects Aged Above 2 Years When Administered According to the Prescribing Information. Completed NCT00290329 Phase 4
21 A Phase IV, Randomized Study to Evaluate the Immune Response of UK Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life Completed NCT00625677 Phase 4
22 An Open Label Randomised Controlled Study to Evaluate the Induction of Immune Memory Following Infant Vaccination With a Glycoconjugate Neisseria Meningitidis Serogroup C Vaccine and to Assess the Immunological Impact of Administering Routine Infant Immunisations in Consistent Versus Alternating Limbs Completed NCT01129518 Phase 4
23 South Australian Meningococcal B Vaccine Herd Immunity Study Completed NCT03089086 Phase 4
24 Assay of the Immunogenicity of Fractional Dose Tetravalent A, C, Y, W135 Meningococcal Polysaccharide Vaccine in Africa Completed NCT00271479 Phase 4
25 A Phase IV Study to Evaluate the Primary and Booster Immune Responses of UK Infants Receiving a Licensed 6-in-1 DTaP/IPV/Hib/HBV Vaccine (Infanrix-HexaTM) With a 13-valent Pneumococcal Conjugate Vaccine and Incorporating a Randomisation Study of a Single Dose of 3 Different Meningococcal Group C Conjugate Vaccines at 3 Months of Age Completed NCT01896596 Phase 4
26 A Single Centre, Open-label, Randomised Clinical Study to Investigate Meningococcal Serogroup A and C Saccharide Specific B Cell Responses in Adult Volunteers to One of Three Regimens of Meningococcal ACWY Conjugate Vaccine or Meningococcal ACWY Polysaccharide Vaccine Priming Doses Followed by a Booster Dose of the Meningococcal ACWY Conjugate Vaccine Completed NCT01593514 Phase 4
27 A Randomized, Controlled Trial to Compare Protection in Adolescents Between Different Meningococcal Immunization Schedules Used in Canada; a Canadian Immunization Research Network (CIRN) Study. Recruiting NCT03694405 Phase 4
28 Postmarketing Surveillance Study for Use of Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in the Republic of Korea Active, not recruiting NCT02864927 Phase 4
29 Babies Born Early Antibody Response to Men B Vaccination: A Phase IV Multicentre Randomised Study to Evaluate the Primary and Booster Immune Responses in UK Preterm Infants Receiving Routine Immunisations and Incorporating a Three Dose Versus a Two Dose Schedule of 4CMenB (Bexsero®) for Primary Immunisation. Active, not recruiting NCT03125616 Phase 4
30 Safety and Immunogenicity Study for Use of Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Healthy Subjects 2-55 Years of Age in India Completed NCT01086969 Phase 3
31 A Phase III, Single Center, Open Label, Uncontrolled Study to Evaluate the Immunogenicity, Safety and Tolerability, of the Chiron Meningococcal C Conjugate Vaccine When Administered to Healthy Premature and Non Premature Children at 3, 5, 11 Months of Age Concomitantly With a Hexavalent Infant Vaccine Completed NCT00310674 Phase 3
32 Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine (GSK 134612) When Co-administered With Routine Vaccines in Healthy Infants and Toddlers Completed NCT01340898 Phase 3
33 Immunogenicity and Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Subjects Aged 9 to 23 Months in India and in the Russian Federation Completed NCT01890759 Phase 3
34 A Phase III, Multi-Center, Open-Label, Controlled, Randomized Study to Evaluate the Immunogenicity, Safety, Tolerability and the Ability to Prime for Memory of Chiron Meningococcal C Conjugate Vaccine When Administered to Healthy Infants as One Dose Given at 2 or 6 Months of Age With a Booster at 12-16 Months of Age, in Comparison to Two Doses in the First Year of Life, Given Two Months Apart, With a Booster at 12-16 Months of Age; and in Comparison to One Dose Given at 12-16 Months of Age Completed NCT00311415 Phase 3
35 A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086 Completed NCT01543087 Phase 3 bivalent rLP2086
36 Safety and Immunogenicity of Two Doses of Menactra® (Meningococcal [Groups A, C, Y, and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) or One Dose of Monovalent Meningococcal Group C Conjugate Vaccine Administered Concomitantly With Routine Immunizations Between 12 and 18 Months of Age in Canada Completed NCT01359449 Phase 3
37 A Phase 3, Multi-center Study to Evaluate Lot to Lot Consistency, Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults and Compare to the Safety and Immune Response to a Licensed Conjugate Meningococcal ACWY Vaccine Completed NCT00450437 Phase 3
38 Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine 134612 With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults at 9-25 Years of Age Completed NCT01755689 Phase 3
39 A Phase 3, Open-Label, Randomized, Multi-Center Study to Evaluate the Safety and Immunogenicity of MMRV Vaccine When Administered Concomitantly With Novartis Meningococcal ACWY Conjugate Vaccine to Healthy Toddlers Completed NCT00626327 Phase 3
40 A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age Completed NCT00616421 Phase 3
41 A Phase 3, Multi-center, Open-label Study to Evaluate Immunogenicity and Safety of Novartis Meningococcal ACWY Conjugate Vaccine (MenACWY-CRM) in Healthy Children, Adolescents and Adults in Russia Completed NCT01725217 Phase 3
42 A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive. Completed NCT01911221 Phase 3
43 A Phase 3, Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 11 to 55 Years of Age in Korea Completed NCT01274897 Phase 3
44 Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Mencevax™ ACWY in Healthy Subjects Aged 18-25 Years Completed NCT01154088 Phase 3
45 A Phase 2b/3, Multi-Center, Observer-Blind, Controlled Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents Aged 11-17 Years According to Different Vaccination Schedules Completed NCT00661713 Phase 2, Phase 3
46 Phase IIIb Immunogenicity, Safety and Reactogenicity Study of GSK Biologicals' Meningococcal Vaccine [GSK 134612] When Given as One Dose to Healthy Subjects Aged 56 Years or Older Completed NCT01235975 Phase 3
47 Immunogenicity and Safety of a Single Dose of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese Subjects Completed NCT01519713 Phase 3
48 Non-inferiority of GSK Biologicals' Meningococcal Vaccine GSK134612 Versus Mencevax™ in Healthy Subjects Aged 2 Through 10 Years of Age Completed NCT00514904 Phase 3
49 A Phase 3b, Randomized, Observer-Blind, Placebo-Controlled Multi-Center Study Comparing Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine, Administered to Healthy Children 2 to 10 Years of Age. Completed NCT01682876 Phase 3
50 Evaluation of the Response to a Single Dose of Menactra® in Adolescents Aged 16 to 19 Years Who Previously Received One Dose of Quadrivalent (A, C, Y, W 135) and at Least One Dose of Bivalent (A, C) Meningococcal Polysaccharide Vaccine in Saudi Arabia. Completed NCT00444951 Phase 3

Search NIH Clinical Center for Meningococcal Infection

Genetic Tests for Meningococcal Infection

Anatomical Context for Meningococcal Infection

MalaCards organs/tissues related to Meningococcal Infection:

40
Brain, Testes, Spleen, Spinal Cord, B Cells, Heart, Kidney

Publications for Meningococcal Infection

Articles related to Meningococcal Infection:

(show top 50) (show all 1510)
# Title Authors PMID Year
1
Carriage prevalence of Neisseria meningitidis in the Americas in the 21st century: a systematic review. 42
31344352 2019
2
Comparison of Immune Responses to Two Quadrivalent Meningococcal Conjugate Vaccines (CRM197 and Diphtheria Toxoid) in Healthy Adults. 42
31197986 2019
3
Immunogenicity and safety of meningococcal group A, C, W and Y tetanus toxoid conjugate vaccine: review of clinical and real-world evidence. 42
31091978 2019
4
Surveillance of penicillin resistance of Neisseria meningitidis strains from invasive infections between 2013 and 2018 in Turkey. 61
32028863 2020
5
Failure of first meningococcal vaccination in patients with atypical haemolytic uraemic syndrome treated with eculizumab. 61
29992261 2020
6
Effectiveness of a single dose of the quadrivalent meningococcal conjugate vaccine, MenACWY-CRM, in the Korean Armed Forces. 61
31787413 2020
7
A Syrian refugee with meningococcal empyema. 61
31922922 2020
8
Distinct roles of the anaphylatoxin receptors C3aR, C5aR1 and C5aR2 in experimental meningococcal infections. 61
31274379 2019
9
Combined vaccines for prophylaxis of infectious conditions. 61
30829068 2019
10
Prevention of Opportunistic Infections in Women With HIV Infection. 61
31433312 2019
11
Atypical, Yet Not Infrequent, Infections with Neisseria Species. 61
31861867 2019
12
The meningococcal vaccine antigen GNA2091 is an analogue of YraP and plays key roles in outer membrane stability and virulence. 61
31442078 2019
13
Eculizumab Safety: Five-Year Experience From the Global Atypical Hemolytic Uremic Syndrome Registry. 61
31890998 2019
14
Complement deficiencies and dysregulation: Pathophysiological consequences, modern analysis, and clinical management. 61
31421540 2019
15
Purpuric rash and fever among hospitalized children aged 0-18 years: Comparison between clinical, laboratory, therapeutic and outcome features of patients with bacterial versus viral etiology. 61
30922715 2019
16
Eliminating Meningococcal Epidemics From the African Meningitis Belt: The Case for Advanced Prevention and Control Using Next-Generation Meningococcal Conjugate Vaccines. 61
31671447 2019
17
Risk of antibiotic resistant meningococcal infections in Hajj pilgrims. 61
31444169 2019
18
Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. 61
30767274 2019
19
Targeting Type IV pili as an antivirulence strategy against invasive meningococcal disease. 61
30911127 2019
20
Immunogenicity profiling of protein antigens from capsular group B Neisseria meningitidis. 61
31048732 2019
21
Inhibitors of the Neisseria meningitidis PilF ATPase provoke type IV pilus disassembly. 61
30948644 2019
22
Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study. 61
30971227 2019
23
Molecular studies of meningococcal and pneumococcal meningitis patients in Ethiopia. 61
30894090 2019
24
Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis. 61
30768680 2019
25
Eculizumab Use for Kidney Transplantation in Patients With a Diagnosis of Atypical Hemolytic Uremic Syndrome. 61
30899871 2019
26
Cost Effectiveness of Meningococcal Serogroup B Vaccination in College-Aged Young Adults. 61
30573332 2019
27
Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. 61
30510079 2019
28
Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. 61
30510080 2019
29
A systematic review of the diagnostic accuracy of Loop-mediated-isothermal AMPlification (LAMP) in the diagnosis of invasive meningococcal disease in children. 61
30732581 2019
30
NHBA is processed by kallikrein from human saliva. 61
31369555 2019
31
Complement-Dependent Serum Bactericidal Assays for Neisseria gonorrhoeae. 61
31119629 2019
32
Genomic surveillance of invasive meningococcal disease in the Czech Republic, 2015-2017. 61
31295279 2019
33
Modeling Neisseria meningitidis Infection in Mice: Methods and Logistical Considerations for Nasal Colonization and Invasive Disease. 61
30877676 2019
34
Diagnosis of Meningococcal Infection Using Internally Controlled Multiplex Real-Time PCR. 61
30877667 2019
35
Meningococcal pneumonia: a review. 61
31463180 2019
36
Clinical and Genetic Spectrum of a Large Cohort With Total and Sub-total Complement Deficiencies. 61
31440263 2019
37
Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance. 61
30039480 2019
38
Analysis of social and medical portrait of children with pertussis, meningococcal infectious, scarlet fever and estimation of their assigned pharmacotherapy. 61
31622270 2019
39
Analysis of C3 Nephritic Factors by ELISA. 61
30539576 2019
40
Design, synthesis, and structural elucidation of novel NmeNANAS inhibitors for the treatment of meningococcal infection. 61
31618227 2019
41
The Meningococcal Cysteine Transport System Plays a Crucial Role in Neisseria meningitidis Survival in Human Brain Microvascular Endothelial Cells. 61
30538184 2018
42
Is primary meningococcal arthritis in children more frequent than we expect? Two pediatric case reports revealed by molecular test. 61
30591016 2018
43
Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study. 61
30120069 2018
44
[Coinfection by astrovirus and Neisseria B meningitidis in a girl]. 61
30204993 2018
45
Epidemics of meningococcal meningitis in Northern Nigeria focus on preventive measures. 61
30588927 2018
46
[Meningococcal infections in Switzerland : changes in epidemiology, clinical manifestations and prophylaxis]. 61
30307136 2018
47
Adhesion to nanofibers drives cell membrane remodeling through one-dimensional wetting. 61
30361638 2018
48
Clinical spectrum and short-term outcome of adult patients with purpura fulminans: a French multicenter retrospective cohort study. 61
30128591 2018
49
Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies. 61
30171081 2018
50
Analysis of the impact of corticosteroids adjuvant treatment during experimental invasive meningococcal infection in mice. 61
29753775 2018

Variations for Meningococcal Infection

Expression for Meningococcal Infection

Search GEO for disease gene expression data for Meningococcal Infection.

Pathways for Meningococcal Infection

Pathways related to Meningococcal Infection according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.53 TTR GSR AGTR1 AGT
2
Show member pathways
12.04 ADRB2 ADRB1 ADD1
3 11.99 SOD1 AGT ADRB2 ADRB1
4
Show member pathways
11.84 AGTR1 ADRB2 ADRB1
5
Show member pathways
11.76 AGTR1 AGT ADRB2 ADRB1
6 11.02 SOD1 C7
7 10.96 AGTR1 ADRB2
8 10.9 SOD1 GSR
9 10.76 AGTR1 AGT ADRB2 ADRB1
10 10.68 ADRB2 ADRB1
11 10.51 GSR G6PD

GO Terms for Meningococcal Infection

Cellular components related to Meningococcal Infection according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.5 TTR SOD1 GSR G6PD CPB2 C7
2 cell GO:0005623 9.17 SOD1 GSR CPB2 C7 AGTR1 AGT

Biological processes related to Meningococcal Infection according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 cellular response to oxidative stress GO:0034599 9.67 SOD1 GSR G6PD
2 activation of adenylate cyclase activity GO:0007190 9.63 ADRB2 ADRB1
3 response to cold GO:0009409 9.62 ADRB2 ADRB1
4 positive regulation of reactive oxygen species metabolic process GO:2000379 9.62 AGTR1 AGT
5 brown fat cell differentiation GO:0050873 9.61 ADRB2 ADRB1
6 positive regulation of cytokine production GO:0001819 9.61 SOD1 AGT
7 regulation of vasoconstriction GO:0019229 9.6 AGTR1 AGT
8 regulation of blood vessel diameter GO:0097746 9.59 AGTR1 ADRB2
9 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.58 ADRB2 ADRB1
10 positive regulation of superoxide anion generation GO:0032930 9.58 SOD1 AGT
11 positive regulation of cellular protein metabolic process GO:0032270 9.57 AGTR1 AGT
12 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.56 AGTR1 AGT
13 cellular sodium ion homeostasis GO:0006883 9.55 C7 AGT
14 low-density lipoprotein particle remodeling GO:0034374 9.54 AGTR1 AGT
15 negative regulation of multicellular organism growth GO:0040015 9.52 ADRB2 ADRB1
16 diet induced thermogenesis GO:0002024 9.51 ADRB2 ADRB1
17 glutathione metabolic process GO:0006749 9.5 SOD1 GSR G6PD
18 positive regulation of cholesterol esterification GO:0010873 9.48 AGTR1 AGT
19 positive regulation of NAD(P)H oxidase activity GO:0033864 9.46 AGTR1 AGT
20 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.43 AGTR1 AGT
21 regulation of renal sodium excretion GO:0035813 9.4 AGTR1 AGT
22 renin-angiotensin regulation of aldosterone production GO:0002018 9.37 AGTR1 AGT
23 positive regulation of extracellular matrix constituent secretion GO:0003331 9.26 CPB2 AGT
24 regulation of blood vessel diameter by renin-angiotensin GO:0002034 9.16 AGTR1 AGT
25 norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure GO:0002025 8.96 ADRB2 ADRB1
26 heat generation GO:0031649 8.62 ADRB2 ADRB1

Molecular functions related to Meningococcal Infection according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.56 TTR AGTR1 ADRB1 ADD1
2 NADP binding GO:0050661 9.32 GSR G6PD
3 adrenergic receptor activity GO:0004935 9.16 ADRB2 ADRB1
4 epinephrine binding GO:0051379 8.96 ADRB2 ADRB1
5 norepinephrine binding GO:0051380 8.62 ADRB2 ADRB1

Sources for Meningococcal Infection

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....